

December 22, 2015

Facilities	Amount (Rs. Crore)	Ratings
<b>Cash Credit</b>	<b>2.00</b>	<b>SMERA BB-/Stable (Assigned)</b>
<b>Working Capital Term Loan</b>	<b>4.14</b>	<b>SMERA BB-/Stable (Assigned)</b>
<b>Letter of Credit</b>	<b>1.00</b>	<b>SMERA A4+ (Assigned)</b>

SMERA has assigned a long term rating of '**SMERA BB-**' (read as SMERA double B minus) and a short term rating of '**SMERA A4+**' (read as SMERA A four plus) to the Rs.7.14 crore bank facilities of Gujarat Themis Biosyn Limited (GTBL). The outlook is '**Stable**'. The rating is supported by the company's long track record of operations, steady profit margins and experienced management. The rating also draws support from the healthy financial risk profile and support from its group company, Themis Medicare Limited. However, the rating is constrained by the low net worth and dependency on Lupin Limited for job work income.

### **Outlook: Stable**

SMERA believes that GTBL will continue to benefit over the medium term from its established presence as a manufacturer of salts and formulations for the pharmaceutical industry. The outlook may be revised to 'Positive' in case the company registers higher than expected improvement in profit margins and financial risk profile. Conversely, the outlook may be revised to 'Negative' in case of deterioration in GTBL's profit margins due to lower than expected job work income from Lupin Limited.

### **Rating Sensitivity Factors**

- Improvement in scale of operations as well as profit margins
- Working capital management
- Renewal of agreement with Lupin Limited

### **About the Company**

GTBL was incorporated in 1981 and commenced production in August 1985. It was subsequently taken over in June 1991 by the Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.

For FY2014-15, GTBL reported profit after tax (PAT) of Rs.4.59 crore on operating income of Rs.31.47 crore as compared with PAT of Rs.4.53 crore on operating income of Rs.30.31 crore for FY2013-14.

**Disclaimer:** A SMERA rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. SMERA ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, SMERA, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. SMERA is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. SMERA ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.smerra.in](http://www.smerra.in)) for the latest information on any instrument rated by SMERA.

**Contact List:**

Media/Business Development	Analytical Contact	Rating Desk
Mr. Anthony Jose, Vice President – Business Development, Mid Corporate Tel : +91-22-6714 1191 Cell : +91 9820802479 Email : <a href="mailto:anthony.jose@smera.in">anthony.jose@smera.in</a> Web: <a href="http://www.smera.in">www.smera.in</a>	Mr. Vinay Chhawchharia Associate Vice President - Corporate Ratings Tel: +91-22-6714 1156 Email: <a href="mailto:yinay.chhawchharia@smera.in">yinay.chhawchharia@smera.in</a>	Tel: +91-22-6714 1184 Email: <a href="mailto:ratingdesk@smera.in">ratingdesk@smera.in</a>

**Disclaimer:** A SMERA rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. SMERA ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, SMERA, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. SMERA is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. SMERA ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.smera.in](http://www.smera.in)) for the latest information on any instrument rated by SMERA.